These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 26934320)
21. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079 [TBL] [Abstract][Full Text] [Related]
22. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932 [TBL] [Abstract][Full Text] [Related]
23. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726 [No Abstract] [Full Text] [Related]
24. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
25. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells. Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447 [TBL] [Abstract][Full Text] [Related]
26. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway. Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549 [TBL] [Abstract][Full Text] [Related]
27. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855 [TBL] [Abstract][Full Text] [Related]
28. miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A. Shao M; Geng Y; Lu P; Xi Y; Wei S; Wang L; Fan Q; Ma W Biochem Biophys Res Commun; 2015 Sep; 464(4):1309-1313. PubMed ID: 26231799 [TBL] [Abstract][Full Text] [Related]
29. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474 [TBL] [Abstract][Full Text] [Related]
30. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886 [TBL] [Abstract][Full Text] [Related]
31. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation. Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474 [TBL] [Abstract][Full Text] [Related]
32. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation. Rho JH; Kang DY; Park KJ; Choi HJ; Lee HS; Yee SB; Yoo YH Int J Oncol; 2005 Aug; 27(2):465-71. PubMed ID: 16010429 [TBL] [Abstract][Full Text] [Related]
33. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592 [TBL] [Abstract][Full Text] [Related]
34. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer. Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616 [TBL] [Abstract][Full Text] [Related]
35. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966 [TBL] [Abstract][Full Text] [Related]
36. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381 [TBL] [Abstract][Full Text] [Related]
37. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356 [TBL] [Abstract][Full Text] [Related]
38. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line. Duo J; Ma Y; Wang G; Han X; Zhang C DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817 [TBL] [Abstract][Full Text] [Related]
39. Synergistic Anticancer Activity of Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361 [TBL] [Abstract][Full Text] [Related]
40. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Zang Y; Kirk CJ; Johnson DE Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]